Cargando…
Repurposing Pomalidomide as a Neuroprotective Drug: Efficacy in an Alpha-Synuclein-Based Model of Parkinson’s Disease
Marketed drugs for Parkinson’s disease (PD) treat disease motor symptoms but are ineffective in stopping or slowing disease progression. In the quest of novel pharmacological approaches that may target disease progression, drug-repurposing provides a strategy to accelerate the preclinical and clinic...
Autores principales: | Palmas, Maria Francesca, Ena, Anna, Burgaletto, Chiara, Casu, Maria Antonietta, Cantarella, Giuseppina, Carboni, Ezio, Etzi, Michela, De Simone, Alfonso, Fusco, Giuliana, Cardia, Maria Cristina, Lai, Francesco, Picci, Luca, Tweedie, David, Scerba, Michael T., Coroneo, Valentina, Bernardini, Renato, Greig, Nigel H., Pisanu, Augusta, Carta, Anna R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130415/ https://www.ncbi.nlm.nih.gov/pubmed/35072912 http://dx.doi.org/10.1007/s13311-022-01182-2 |
Ejemplares similares
-
Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders
por: Jung, Yoo Jin, et al.
Publicado: (2021) -
Neuroprotection by the Immunomodulatory Drug Pomalidomide in the Drosophila LRRK2(WD40) Genetic Model of Parkinson’s Disease
por: Casu, Maria Antonietta, et al.
Publicado: (2020) -
Modeling Parkinson’s Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers
por: Boi, Laura, et al.
Publicado: (2020) -
The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex
por: Palmas, Maria Francesca, et al.
Publicado: (2022) -
Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy?
por: Carta, Anna R., et al.
Publicado: (2011)